Ocata Therapeutics Inc fka OCAT

[rumper]

Ocata Could Potentially Cure 90% Of Legal Blindness

Wet macular degeneration accounts for approximately 10 percent of cases, but results in 90 percent of legal blindness.
http://www.brightfocus.org/macular/about/understanding/facts.html


Wet macular degeneration is usually preceded by the dry form of the disease. This wet form occurs when the Bruch’s membrane begins to break down,
usually near drusen deposits, and new blood vessels grow. This growth is called neovascularization. These vessels are very fragile and can leak fluid and blood, resulting in scarring of the macula and the potential for rapid, severe damage.

http://www.brightfocus.org/docs/fact-sheets-in-pdf-format/macular_degeneration_frequently_asked_questions.pdf


Eylea is for wet macular degeneration only, and sales
are skyrocketing.

Tarrytown, New York-based Regeneron said it expected net sales of Eylea to be 25 percent to 30 percent higher this year than in 2014, when the eye drug raked in global sales of $1.74 billion.
http://www.reuters.com/article/2015/02/10/regeneron-pharm-results-idUSL4N0VK52620150210


Ocata's Share Count is: 35,667,442

And 1 billion of market cap represents
a share price of $28 dollars.

This is the likely starting point of a buyout.

We'll see.

Tiny, Tiny Share Count!
100% Safe Phase 1 Success
Strong Unexpected Efficacy Signal
Patents Galore